
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio is a promising company with an innovative pipeline of off-the-shelf gamma delta T cell therapies for autoimmune diseases and cancer. While the company may face clinical risks related to safety, their products have shown potential for mitigating adverse events compared to other cell therapies. Furthermore, the company has a strong financial outlook, with a recent product sales increase and potential for continued growth based on the success of their most advanced product candidate, prulacabtagene leucel.
Bears say
Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Despite showing promising efficacy in LN/SLE patients, there are several potential risks and uncertainties surrounding Adicet's main product candidate, prulacabtagene leucel (prula-cel). These include potential regulatory hurdles, such as FDA approval for Vδ1 gamma-delta T-cell therapies, and currency risks associated with future royalty payments. Additionally, Adicet's competition in the highly competitive autoimmune landscape could pose challenges for the company's success. As a result, the negative outlook for Adicet Bio's stock is largely based on these potential risks and uncertainties.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares